Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. director David Charles Lubner reported a bona fide gift of 53,625 shares of Common Stock on April 24, 2026. The transfer was recorded at $0.00 per share, and his directly owned holdings of this stock are now reported as 0 shares following the gift.
Dyne Therapeutics director-affiliated funds reported open-market sales of 384,549 shares of common stock at prices generally around $18–$19 per share. The trades on April 23–27 were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas Venture funds and related partnerships, including Atlas Venture Opportunity Fund II, Atlas Venture Fund XI, AVA XI LP, and Atlas Venture Opportunity Fund I. Jason P. Rhodes is a member of the relevant general partner entities and disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.